Zydus' receives supplemental Abbreviated New Drug Application (sANDA) approval from the USFDA for manufacturing of Doxycycline Injection at Jarod, Vadodara

Zydus Cadila has received approval for its supplemental Abbreviated New Drug Application (SANDA) for Doxycycline Injection USP, 100 mg/Vial from the US FDA. The product will be manufactured at Cadila Healthcare Ltd's injectable facility at Jarod, Vadodara (formerly known as Liva Pharmaceuticals Ltd). The state-of-the-art facility is equipped with manufacturing lines that can handle both liquid and lyophilised products based on vials and cartridges presentation.

Doxycycline USP is the first product approval at the second combined Liquid plus Lyophilised Vials Injectable line at the Jarod facility. This facility is an important one for Zydus' US Injectable portfolio as five ANDAs have been approved from this facility and another six have been filed, awaiting approval. Zydus has plans to file further ANDAs and NDAs from this facility. This approval will also help ramp up site transfer approvals from the Moraiya facility to this facility.

The group now has 293 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.354.3 as compared to the previous close of Rs. 353.65. The total number of shares traded during the day was 91334 in over 1884 trades.

The stock hit an intraday high of Rs. 359.7 and intraday low of 353.5. The net turnover during the day was Rs. 32509953.

Source : Equity Bulls

Keywords